drug development, biotechnology

Super-resolution imaging identifies abnormalities in the hair-like protrusions on a cell’s surface and may help facilitate earlier detection of primary ciliary dyskinesia.

Submit your new product by the end of the day Monday to have a chance at being selected for a coveted spot in The Scientist's 2019 competition.

From single-cell analysis to whole-genome sequencing, this year's best new products shine on many levels.

A report finds that new medications still take about 12 years to go from patent to patient.

A biotech company reports that an experimental treatment elongated its CEO’s telomeres. 

A second patient taking an experimental medication to treat Prader-Willi Syndrome has died of blood clots.

Some say the biotech bubble has burst over concerns that drug prices are too high—and may soon be regulated.

The US Food and Drug Administration green lights the first medicine produced by a 3-D printer for use in the human body.

Biotech firm likely to pull the plug after its gene therapy product fails.

Johnson & Johnson agrees to use Emulate’s blood-clot device in three of its preclinical drug programs.

As medical marijuana businesses set up shop across the U.S., a handful of companies are taking the pharmaceutical route, guiding cannabis-derived drugs through clinical trials.

With an infusion of public and private resources and accelerated regulatory processes, a handful of companies are racing to develop a vaccine to curb the Ebola epidemic.

The case marks the first person to contract the virus outside of West Africa.

Regulators must consider both the promise and potential pitfalls of new technologies when determining whether to move them into clinical trials.

New analysis finds that the size of a company is not tied to getting a drug to market.

ALS patients take their fate into their own hands, self-administering an unapproved chemical and collating their results online.

Industry experts discuss the agency’s plans to make the drug approval process more transparent.

Whether working for a pharmaceutical giant or a biotech start-up with a unique vision, researchers who responded to this year’s Best Places to Work in Industry survey are translating society’s most pressing scientific needs into a new generation of drugs, research tools, and cutting-edge innovations.

Much has changed in the 10 years since our first survey of industry researchers. Large companies are now looking to small, nimble ones for services as well as innovation.

The US Food and Drug Administration has relaxed some of the rules governing how companies must test the sterility of materials used to make biologic drugs.